<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00338390</url>
  </required_header>
  <id_info>
    <org_study_id>EUROPA</org_study_id>
    <secondary_id>2004-003749-42</secondary_id>
    <nct_id>NCT00338390</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Changes in CD4 on Replacing TDF With ABC or DDI+TDF With ABC+3TC</brief_title>
  <official_title>Study of Changes in CD4 Lymphocyte Count in Patients With a HAART Regimen Including DDI + Tenofovir and With Viral Suppression Following the Replacement of Tenofovir With Abacavir Once Daily or Following the Double Replacement of DDI + Tenofovir With Abacavir + Lamivudine in a Single Tablet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Granollers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Granollers</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to ascertain whether the sole replacement of tenofovir with abacavir once a
      day improves the immunological response obtained with tenofovir + ddI or whether it is better
      to perform a double replacement of tenofovir and ddI with abacavir + lamivudine (joint
      formulation) in a single daily dose to achieve these objectives.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Different works have shown a high rate of virological failure among patients on abacavir +
      lamivudine + tenofovir or ddI + 3TC + tenofovir, thus rendering the use of these combinations
      actively unadvisable.

      Furthermore, recent studies have also shown that ABC+3TC are associated with a significantly
      higher increase in CD4 than the current treatment standard formed by AZT+3TC. This provides
      us with grounds to suppose that patients with TDF+ddI may recover their CD4 with ABC+3HT.
      Similarly, and recently, the existence of pharmacokinetic interactions between tenofovir +
      abacavir has begun to be questioned.

      Finally, the replacement of tenofovir with abacavir or tenofovir + ddI with abacavir +
      lamivudine does not detract from the potency of HAART, the toxicity profile is different and
      their behaviour at mitochondrial level is similar.

      This study aims to ascertain whether the sole replacement of tenofovir with abacavir once a
      day improves the immunological response obtained with tenofovir + ddI or whether it is better
      to perform a double replacement of tenofovir and ddI with abacavir + lamivudine (joint
      formulation) in a single daily dose to achieve these objectives.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients that increase their number of CD4 lymphocytes with regard to the baseline.</measure>
    <time_frame>At 12, 24, 36 and 48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the proportion of patients with viral load of HIV-1 &lt;50 copies of the combinations studied during the follow-up period.</measure>
    <time_frame>At 12, 24, 36 and 48 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new clinical adverse events that appear .</measure>
    <time_frame>during 48 weeks of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the clinical adverse events that were already present at the time they were included in the study.</measure>
    <time_frame>during the 48 weeks of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of treatment drop-outs due to the appearance of adverse events</measure>
    <time_frame>during the 48 weeks of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new laboratory alterations that appear during the follow-up period (change in renal parameters, changes in lactate levels, modification of pancreatic enzymes, changes in lipid parameters).</measure>
    <time_frame>during the follow-up period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the laboratory alterations that were already present at the time they were included in the study.</measure>
    <time_frame>during the 48 weeks of follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Maintain antiretroviral treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Change tenofovir to abacavir and increase didanosine dose to 400 mg/day if weight is &gt; 60 Kg. or to 250mg/day if weight is &lt; 60 kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Change tenofovir and didanosine to abacavir + lamivudine (600mg+300 mg/day in one single tablet).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abacavir</intervention_name>
    <description>Change tenofovir to abacavir</description>
    <arm_group_label>2</arm_group_label>
    <other_name>n/h.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine</intervention_name>
    <description>Increase didanosine dose to 400 mg/day if weight is &gt; 60 Kg. or to 250mg/day if weight is &lt; 60 kg.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>n/h.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abacavir+Lamivudine</intervention_name>
    <description>Change tenofovir and didanosine to abacavir + lamivudine (600mg+300 mg/day in one single tablet).</description>
    <arm_group_label>3</arm_group_label>
    <other_name>n/h.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years.

          -  HIV-1 infected patients.

          -  Patients on triple HAART therapy including ddI + tenofovir plus a PI or NNRTI for at
             least 3 months.

          -  Patients with an undetectable HIV-1 viral load (&lt; 50 copies RNA / mL or &lt; centre's
             limit of detection) over the last 6 months.

          -  Not be on treatment with immunosuppressives, such as: hydroxyurea, interferon,
             ribavirin or cytostatics.

          -  Not be on treatment with interleukin-2 or other immunomodulators.

          -  Women may not be of fertile age (defined as at least one year from menopause or
             undergoing any surgical sterilisation technique), or must undertake to use a barrier
             contraceptive method during the study.

          -  Signature of the informed consent.

        Exclusion Criteria:

          -  Incapacity to give informed consent.

          -  Bad adherence or treatment interruptions over the previous 6 months.

          -  Prior exposure to abacavir.

          -  HAART Therapy including ddI at a dose of 400mg + tenofovir if weight &gt; 60 kg or ddI
             250 mg + tenofovir if weight &lt; 60 kg.

          -  Suspicion of cross resistances to abacavir and lamivudine.

          -  Hepatic or pancreatic analytical alterations 4 times above the limit of normality.

          -  Presence of opportunistic infections and/or recent tumours (&lt; 6 months).

          -  Patients participating in another clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enric Pedrol, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Hospital de Granollers</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Germans Trias i Pujol Hospital</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Jaume de Calella</name>
      <address>
        <city>Calella</city>
        <state>Barcelona</state>
        <zip>08370</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Mataró</name>
      <address>
        <city>Mataro</city>
        <state>Barcelona</state>
        <zip>08304</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Basurto</name>
      <address>
        <city>Bilbao</city>
        <state>Bilabao</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. del S.A.S. Jerez de la Frontera</name>
      <address>
        <city>Jerez de la Frontera</city>
        <state>Cádiz</state>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundació Hospital de Granollers,</name>
      <address>
        <city>Barcelona</city>
        <state>Granollers</state>
        <zip>08400</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arquitecto Marcide</name>
      <address>
        <city>El Ferrol</city>
        <state>La Coruña</state>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sierrallana</name>
      <address>
        <city>Torrelavega</city>
        <state>Santander</state>
        <zip>39300</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Castellón, , Castellón,</name>
      <address>
        <city>Castello</city>
        <zip>12004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. San Fco Borja Gandia</name>
      <address>
        <city>Gandia</city>
        <zip>46700</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cabueñes</name>
      <address>
        <city>Gijon</city>
        <zip>33394</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Cecílio</name>
      <address>
        <city>Granada</city>
        <zip>18012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Jiménez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Joan XXIII</name>
      <address>
        <city>Tarragona</city>
        <zip>43007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Xeral de Vigo</name>
      <address>
        <city>Vigo</city>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2006</study_first_submitted>
  <study_first_submitted_qc>June 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2006</study_first_posted>
  <last_update_submitted>March 19, 2015</last_update_submitted>
  <last_update_submitted_qc>March 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <keyword>Antiretrovirals</keyword>
  <keyword>CD4 cell count</keyword>
  <keyword>toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Dideoxynucleosides</mesh_term>
    <mesh_term>Didanosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

